Combinatorial drug screening identifies synergistic co-targeting of Bruton's tyrosine kinase and the proteasome in mantle cell lymphoma.
about
Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinibp70S6 kinase is a critical node that integrates HER-family and PI3 kinase signaling networks.Synergistic apoptosis in head and neck squamous cell carcinoma cells by co-inhibition of insulin-like growth factor-1 receptor signaling and compensatory signaling pathways.BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future.The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.Target identification for biologically active small molecules using chemical biology approaches.Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemiaIbrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia.Are we a step forward with targeted agents in resolving the enigma of mantle cell lymphoma?Novel agents in mantle cell lymphoma.Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas.Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways.Microenvironmental agonists generate phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL
P2860
Q26995113-64EB241A-E96F-4A3F-8069-BD826C01B286Q30371561-7CA1CF2B-37B0-4A79-BEED-FB9EBF9B6B70Q30458494-0513E098-BAF7-40D8-A7C4-7EF0DE8618BDQ34041311-09654CD6-00AC-4296-AFDE-CB8A35BAEFC1Q35889653-ACEA7F39-A023-435E-94D2-90C1D6FF74C4Q36069749-36251863-3E4A-4C8A-AC52-058C36903124Q37180382-E566124F-8276-4AEB-AD5F-6B027766B676Q37688589-D05155B8-460C-4BBE-B8AB-A200BBDCB3E1Q38382492-8DDF8B4B-82D2-4F77-B324-59703F0FF0D6Q38516704-D5ACE31F-9BF7-4BC6-96BD-F506B2CE838AQ39933783-80A2795F-652E-4898-88E1-2CAD9EB9A6B4Q55070853-7AE24C83-47E7-41DA-8E88-70CEE73C654EQ56514276-063F22F7-847E-4DE1-8630-35088C9D6D1B
P2860
Combinatorial drug screening identifies synergistic co-targeting of Bruton's tyrosine kinase and the proteasome in mantle cell lymphoma.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Combinatorial drug screening i ...... asome in mantle cell lymphoma.
@en
Combinatorial drug screening i ...... asome in mantle cell lymphoma.
@nl
type
label
Combinatorial drug screening i ...... asome in mantle cell lymphoma.
@en
Combinatorial drug screening i ...... asome in mantle cell lymphoma.
@nl
prefLabel
Combinatorial drug screening i ...... asome in mantle cell lymphoma.
@en
Combinatorial drug screening i ...... asome in mantle cell lymphoma.
@nl
P2093
P2860
P356
P1433
P1476
Combinatorial drug screening i ...... asome in mantle cell lymphoma.
@en
P2093
A T Tamayo
M E Williams
P2860
P2888
P304
P356
10.1038/LEU.2013.249
P577
2013-08-27T00:00:00Z
P5875
P6179
1002262712